GoodRx reported Q4 2022 total revenue of $184.1 million, exceeding guidance. Subscription revenue grew 42% year-over-year. Over 7 million Americans used GoodRx for their healthcare needs in the fourth quarter.
Total revenue of $184.1 million, exceeding previously announced guidance.
Net loss of $2.01 million; Net loss margin of 1.1%.
Adjusted EBITDA of $49.6 million; Adjusted EBITDA Margin of 26.9%, exceeding previously announced guidance.
Exited the quarter with over 7 million consumers of prescription-related offerings.
For the first quarter and full year 2023, management is anticipating total revenue of approximately $181 million to $183 million for Q1 and $780 million to $790 million for the full year. Adjusted EBITDA margin for the first quarter and full year 2023 is expected to be in the mid-twenty-percent range.
Visualization of income flow from segment revenue to net income